A new nano-immunotherapy uses nanoparticles loaded with anticancer drugs and dual antibodies (e.g., against CD47 and PD-L1) to deliver drugs directly to cancer cells while enhancing both innate and adaptive immune responses and minimizing toxicities. Here, CD47 is linked to cancer.